Purespring Therapeutics

Purespring Therapeutics is a clinical-stage gene therapy company focused on developing treatments for kidney diseases. Founded and led by Professor Moin Saleem, a leading kidney disease expert and consultant nephrologist, Purespring is pioneering gene therapy approaches to address conditions that currently have few effective treatments.

The company's platform leverages adeno-associated virus (AAV) gene therapy delivered directly to the kidney to correct the underlying genetic causes of debilitating kidney conditions. Purespring is backed by Syncona Partners, a specialist life sciences investor, alongside British Patient Capital, Forbion Capital Partners, Gilde Healthcare Partners and Sofinnova Partners.

In October 2024, Purespring raised £80 million to advance its kidney gene therapy pipeline into clinical development.